- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02972684
Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery With Cardiopulmonary Bypass (IMOTEC)
Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery Using Conventional Blood Coagulation Tests or Thrombo-elastographic Point of Care Test - IMOTEC
Peri operative haemorrhage following cardio Pulmonary Bypass may occur in 5 to 10% of cardiac surgical interventions.
Treatment of such complication often necessitates various combinations therapeutic intervention including allogenic blood products administration, drug use and/or surgical intervention. All are expensive treatment and decision making is guided by patient clinical status and biological tests of the haemostatic function.
A key point is the time frame of the clinical process. Therapeutic choices have to be done as fast as possible to minimize bleeding consequences on patient haemodynamic and physiological status. Conventional coagulation test results availability time usually exceed 45' after blood drawing. In such situation, the results may not reflect precisely the coagulation system current state. This downside is often counterbalanced by clinicians empirical choices preceding lab test results knowledge that may conduct to inappropriate treatment, blood product overuse and undue expense.
Viscoelastic point of care test may compensate for the limitations of conventional coagulation tests. In perioperative haemorrhage, faster and more precise information about haemostatic function may help for more accurate therapeutic choices.
The IMOTEC study aims to compare haemorrhage management following cardiac surgery using conventional blood coagulation tests or thrombo-elastogaphic point of care test.
Primary endpoint is a cost utility analysis of the technology and secondary endpoints include blood component transfusion, postoperative bleeding , thoracic re-intervention, postoperative infection (any cause), organ failure, in hospital length of stay and death.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The research is a real life, prospective, single blinded stepped wedge randomized study.
Inclusion after informed consent of adult patient having cardio-vascular surgical procedure using cardiopulmonary bypass and meeting inclusion criterion "bleeding".
After meeting inclusion criterion patients are managed either using conventional blood coagulation tests or using thrombo-elastometry POC test and predefined therapeutic interventions described in a specific algorithm.
Other elements of patient clinical management follow usual center standard care .
Follow up of EQ-5D and clinical evaluations are performed at one , 6 and 12 months after inclusion.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France
- Angers University Hospital
-
Bordeaux, France
- Bordeaux university hospital
-
Caen, France
- CAEN university Hospital
-
Clermont-Ferrand, France
- Clermont-Ferrand University Hospital
-
Dijon, France
- Dijon University Hospital
-
Lille, France
- Lille University Hospital
-
Marseille, France
- Marseille AP-HM La Timone
-
Nancy, France
- Nancy University Hospital
-
Paris, France
- APHP, La Pitié Salpétrière
-
Paris, France
- HEGP, Hôpital Européen Georges Pompidou
-
Rouen, France
- Rouen university hospital
-
Saint-Etienne, France
- Saint-Etienne University Hospital
-
Strasbourg, France
- Strasbourg Universtiy Hospital
-
Toulouse, France
- Toulouse University Hospital
-
Tours, France
- Tours university Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Pre-Inclusion Criteria:
- Adult patients over 18 years old scheduled for elective or urgent cardiac surgery using cardiopulmonary bypass .
- Patient informed written consent (non-opposition to data use) or person of trust or family member information .
Inclusion Criteria:
Blood Coagulation test sampling indication for intra or post-operative bleeding defined as follow:
intra-operative post CPB bleeding; evaluation more than 10min after heparin reversal by protamin.
- Clinically significant bleeding judged on surgeon and anesthesiologist consensual point of view
- Sternal closure delay
- Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h)
Postoperative period , evaluation in post operative care environment after 30min stabilization period
- Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h)
- Patient requiring surgical re-exploration for diagnosed or suspected pericardial effusion or surgical site bleeding requiring surgical hemostatic intervention
Exclusion Criteria:
- Known congenital bleeding disorder
- Redo surgery for patient previously included in the study
- Implantation of Cardiac support device, Extra Corporeal Membrane Oxygenation (ECMO) Extra Corporeal Life support (ECLS), uni or bi-ventricular artificial hearts.
- Indication for post-CPB ECMO or ECLS
- blood transfusion refusal
- pregnant women
- patients under 18 years old
- Adult patient under guardianship, trusteeship or safeguard justice
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Conventional coagulation management
management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
|
|
Experimental: Thrombo-elastometry POC testing
management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
|
Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost-utility ratio
Time Frame: one year
|
incremental cost per incremental life year and incremental costs per incremental QALY
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incremental cost effectiveness ratio
Time Frame: one year
|
incremental cost effectiveness ratio : difference in costs divided by the difference in mortality and serious adverse events
|
one year
|
Complication rates
Time Frame: one year
|
Parameters followed during hospitalization are: volume of postoperative bleeding, allogeneic blood product transfusion, blood cell count, postoperative complications: surgical reexploration, acute kidney injury, need for renal replacement therapy, organ failure, acquired infections, mechanical ventilation duration, intensive care, and in hospital length of stay, death.
|
one year
|
Complication rates
Time Frame: one year
|
The major complications that can occur within 12 months are: death, cardio-thoracic surgical intervention, acute kidney injury, need for renal replacement therapy, any serious illness diagnosis.
|
one year
|
Evaluation survey
Time Frame: Day 1
|
Evaluation survey regarding the context and the parameters that impacted the physician's decision, which will be used a sub-group of 100 patients.
|
Day 1
|
The location of the Thrombo-elastometry POC testing
Time Frame: three years
|
The location of the Thrombo-elastometry POC testing (operative room or laboratory)
|
three years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bertrand Rozec, PUPH, Nantes university hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC16_0009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Coagulation Disorders
-
VarmX B.V.RecruitingCoagulation DisorderNetherlands
-
Groupe Hospitalier Paris Saint JosephCompletedCoagulation DisorderFrance
-
Cairo UniversityRecruitingCoagulation DisorderEgypt
-
Stony Brook UniversityCompletedCoagulation DisorderUnited States
-
HemoSonics LLCCompleted
-
TakedaTakeda Development Center Americas, Inc.RecruitingCoagulation DisorderUnited States, Spain, Belgium, France, Netherlands
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
VarmX B.V.Completed
-
HemoSonics LLCIRCCS Policlinico S. DonatoCompletedCoagulation DisorderItaly
Clinical Trials on Thrombo-elastometry POC testing
-
Wroclaw Medical UniversityUnknownInfluenza | Vaccination | Attitude of Health PersonnelPoland
-
University of WashingtonNational Institute of Mental Health (NIMH); Harvard UniversityCompleted
-
University of WashingtonNational Institute of Mental Health (NIMH)Enrolling by invitationPrEP | HIV | PMTCT | Linkage to Care | ART AdherenceUganda
-
University of WashingtonCompletedHIVSouth Africa, Uganda
-
University of Alabama at BirminghamUniversity of Colorado, Denver; National Institute of Mental Health (NIMH); University... and other collaboratorsCompletedChronic HIV InfectionKenya
-
Foundation for Professional Development (Pty) LtdNational Institutes of Health (NIH); University of California, Irvine; National... and other collaboratorsCompletedTuberculosis, Pulmonary | HouseholdsSouth Africa
-
Clinton Health Access Initiative Inc.Ministry of Health and Child Welfare, ZimbabweCompletedHIV InfectionsZimbabwe
-
Peter KristensenRecruitingDiabetes Mellitus, Type 2Denmark
-
Goethe UniversityUnknownCoagulopathy During Cardiac SurgeryGermany, Austria
-
Vanderbilt UniversityNational Institutes of Health (NIH)CompletedHIV | Suspected Damage to Fetus From Viral Disease in the MotherNigeria, Niger